poisar

Stocks · News reference

8-K filing — Pasithea Therapeutics Corp. (KTTA)

SEC EDGARAug 21, 2026, 9:05 PMSEC EDGAR

Filed: 2026-08-21 AccNo: 0001213900-26-092672 Size: 240 KB Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
edgar
Observed
Aug 21, 2026, 9:05 PM
Checked
Aug 21, 2026, 9:05 PM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. BenzingaJul 21, 2026, 11:20 AMBenzinga Newsdesk

    Pasithea Therapeutics To Present Phase I Dose-Escalation Study Of Safety, Pharmacokinetics Of PAS-004, Macrocyclic MEK Inhibitor, For Treatment Of MAPK Pathway Driven Advanced Solid Tumors At ESMO Congress 2026

    -- Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of PAS-004, a Macrocyclic MEK Inhibitor, for the Treatment of Patients with MAPK Pathway Driven Advanced Solid Tumors will be presented Friday, October

    Read original at benzinga
  2. Globenewswire IncJul 2, 2026, 2:41 PMUnknown

    NOTICE TO DISREGARD -- Thea Foundation

    THEA, a predictive behavioral AI network focused on risk markets, announced $8 million in financing led by Maven11 Capital. However, the article begins with a retraction notice advising readers to disregard the original news release, creating significant uncertainty about the announcement's validity.

    Read original at globenewswire-inc